INDIANAPOLIS — Indy metro police and its community partners will be supported by up to 70 pairs of boots on the ground from dozens of Indianapolis churches and the TenPoint Coalition, which w… ...

TenPoint Coalition, churches to walk with downtown crowds this weekend Kansas deputies pull over 80s rock star en route to show Jay Leno Criticizes Political Late-Night Hosts: "Nobody Wants to ...

INDIANAPOLIS–The TenPoint Coalition plans to have a presence in Indianapolis all throughout the weekend, but especially on Saturday night with the WNBA All-Star game and the Indiana Black Expo taking ...

Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments ...

Seasoned Financial Executive to Lead Strategic Financial Planning and Capital Market Activities as Tenpoint Advances Toward Commercialization Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global ...

"The CrossBow 2D-fabric de-couples system parts so that each component can be developed and verified independently of other components, adding value in building programmable systems by reducing ...

Pre-walk training for Fort Wayne TenPoint participants is rightly described as rigorous, conducted by Harrison and Indianapolis TenPoint members, both in Fort Wayne as well as “on the job ...

The Garmin Xero C1 Pro is a chronograph of the Doppler radar variety that projects a beam downrange toward the target. This allows the unit to rest on the shooting bench behind the muzzle of the gun.

Tenpoint Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for Brimochol PF (carbachol/brimonidine tartrate), a novel fixed-dose combination eye drop therapy for ...

About Tenpoint Therapeutics Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.

Austin, April 07, 2025 (GLOBE NEWSWIRE) -- The Vapor Deposition Market is projected to reach USD 61.03 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.85% from 2024 to 2032.

As chief commercial officer, Carol Kearney will oversee preparations to launch a rival to AbbVie’s age-related blurry near vision product Vuity.